Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cantor Fitzgerald
Accenture
Dow
AstraZeneca
Fuji
Mallinckrodt
UBS
Daiichi Sankyo

Generated: June 24, 2018

DrugPatentWatch Database Preview

Mometasone furoate - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for mometasone furoate and what is the scope of mometasone furoate freedom to operate?

Mometasone furoate
is the generic ingredient in six branded drugs marketed by Merck Sharp Dohme, Fougera Pharms, G And W Labs, Glenmark Generics, Taro, Tolmar, Intersect Ent Inc, Perrigo Israel, Perrigo New York, Amneal Pharms, and Apotex Inc, and is included in twenty-six NDAs. There are thirteen patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Mometasone furoate has seventy patent family members in thirty-four countries.

There are twenty-nine drug master file entries for mometasone furoate. Twenty suppliers are listed for this compound.
Pharmacology for mometasone furoate
Medical Subject Heading (MeSH) Categories for mometasone furoate
Synonyms for mometasone furoate
(11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
(11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione
(1R,2S,10S,11S,13R,14R,15S,17S)-1-CHLORO-14-(2-CHLOROACETYL)-17-HYDROXY-2,13,15-TRIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-3,6-DIEN-14-YL FURAN-2-CARBOXYLATE
(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate
(9beta,10alpha,11alpha,14beta,16alpha,17alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloranyl-17-(2-chloranylethanoyl)-10,13,16-trimethyl-11-oxidanyl-3-oxidanylidene-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
04201GDN4R
11?,16?)-9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate
2-furancarboxylic acid [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloro-1-oxoethyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] ester
83919-23-7
9,21-dichloro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
9,21-Dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)
919M237
A840685
AB2000407
AC-941
AC1L9AZS
AK163902
AKOS015994732
AN-15438
Asmanex
Asmanex HFA
Asmanex Twisthaler
BC228151
BDBM50148733
BPBio1_000424
BRD-K60640630-001-03-7
BRN 4340538
BSPBio_000384
C07817
C27H30Cl2O6
CAS-83919-23-7
CCG-220572
CHEBI:47564
CHEMBL1161
CS-2389
D00690
Danitin
DR003147
DSSTox_CID_3333
DSSTox_GSID_23333
DSSTox_RID_76981
DTXSID4023333
Ecural
Elocon
Elocone
Elomet
Flumeta
HMS1569D06
HMS2096D06
HMS2235I14
HY-13693
KS-00000SPL
KS-1275
LAS 41002
M2354
MLS002153879
MolPort-003-849-257
Mometasone 17-(2-furoate)
mometasone 17-furoate
mometasone furancarboxylate
Mometasone furoate (JAN/USP)
Mometasone furoate [USAN:USP:JAN]
Mometasone furoate hydrate
Mometasone Furoate Impurity G
MOMETASONE FUROATE MONOHYDRATE
Mometasone furoate, >=98% (HPLC)
Mometasone furoate, European Pharmacopoeia (EP) Reference Standard
Mometasone Furoate, pharmaceutical secondary standard; traceable to USP, PhEur and BP
Mometasone furoate, United States Pharmacopeia (USP) Reference Standard
Monovo
Nasonex
NCGC00016950-01
NCGC00179578-01
NCGC00179578-03
NCGC00179578-04
Nosorex
NSC-746171
NSC746171
Ovixan
PL071566
Pregna-1,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)-
Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11beta,16alpha)-
Prestwick_924
Prestwick0_000572
Prestwick1_000572
Prestwick2_000572
Prestwick3_000572
Q-101380
Rimelon
s1987
Sch 32088
Sch-32088
SCHEMBL4568
Sinuva
SMR001233233
SPBio_002603
SR-01000841209
SR-01000841209-2
ST24048112
TL8005500
Tox21_110705
Tox21_110705_1
UNII-04201GDN4R
WOFMFGQZHJDGCX-ZULDAHANSA-N
ZINC3938677

US Patents and Regulatory Information for mometasone furoate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glenmark Generics MOMETASONE FUROATE mometasone furoate CREAM;TOPICAL 078541-001 May 28, 2008 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme ELOCON mometasone furoate OINTMENT;TOPICAL 019543-001 Apr 30, 1987 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for mometasone furoate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme ASMANEX HFA mometasone furoate AEROSOL, METERED;INHALATION 205641-001 Apr 25, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for mometasone furoate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,662,142 Sinus delivery of sustained release therapeutics ➤ Try a Free Trial
7,686,798 Sinus delivery of sustained release therapeutics ➤ Try a Free Trial
7,691,094 Sinus delivery of sustained release therapeutics ➤ Try a Free Trial
7,951,132 Sinus delivery of sustained release therapeutics ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for mometasone furoate

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1998 Austria ➤ Try a Free Trial PRODUCT NAME: MOMETASON FUROAT MONOHYDRAT; NAT. REGISTRATION NO/DATE: 1-22208 19971111; FIRST REGISTRATION: FR AMM 343012.6 19970219
C/GB97/064 United Kingdom ➤ Try a Free Trial PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410
0012 Netherlands ➤ Try a Free Trial 980012, 20110905, EXPIRES: 20160905
80012 Netherlands ➤ Try a Free Trial PRODUCT NAME: MOMETASONI FUROAS MONOHYDRATUM; NAT. REGISTRATION NO/DATE: RVG 21613 19971209; FIRST REGISTRATION: FR NL22055 19970219
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Cantor Fitzgerald
McKinsey
AstraZeneca
UBS
Daiichi Sankyo
Julphar
Queensland Health
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.